News Edmonton -TheNewswire -January 21, 2022 - Innovotech Inc. (TSXV:IOT), a pioneer in the field of biofilm product development, today reported that the Material Transfer and Collaboration Agreement with a global medical device company, announced on July 14, 2020, for Innovotech’s InnovoSIL™-1 silver periodate antimicrobial compound, has been terminated.
InnovoSIL™-1 antimicrobial silver’s performance in terms of biocompatibility and antimicrobial activity was not a factor in the termination of the Agreement.
InnovoSIL™-1 antimicrobial silver continues to show outstanding antimicrobial performance, demonstrating anti-adherent and antibiofilm properties under a variety of challenging test conditions. Innovotech is presently working with three industry collaborators who are pursuing a variety of applications for InnovoSIL™-1 antimicrobial silver and expects to sign a Material Transfer Agreement with a fourth collaboration partner in the next few days.